Physician profile
Usman Khan
NPI 1346658416
$6,652.24
in general payments reported to CMS, 2019-2025
59 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $192 · 2021: $399 · 2022: $1,308 · 2023: $1,591 · 2024: $1,736 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,479 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,479.31 |
| Education | $273.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $563.61 | 2021-2025 | |
| Gilead Sciences, INC. | $501.83 | 2023-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $494.03 | 2020-2025 | Enhertu, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $432.56 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Celgene Corporation | $362.47 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Incyte Corporation | $267.47 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Novartis Pharmaceuticals Corporation | $252.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $231.27 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Daiichi Sankyo INC. | $227.36 | 2020-2025 | Enhertu, Datroway |
| Seagen INC. | $211.79 | 2020-2023 | Padcev, Adcetris, Tivdak |
| Medtronic, INC. | $204.28 | 2022-2025 | Venaseal |
| Exelixis INC. | $169.53 | 2021-2024 | Cabometyx |
| Janssen Biotech, INC. | $139.65 | 2021-2025 | Tecvayli, Balversa, Erleada |
| Astellas Pharma US INC | $134.21 | 2024-2025 | Vyloy, Xtandi |
| Adaptive Biotechnologies Corporation | $127.86 | 2023-2025 | Clonoseq |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $122.67 | 2020-2023 | Imbruvica |
| Sobi, INC | $117.63 | 2022-2024 | |
| Beigene USA, INC. | $111.82 | 2021-2024 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $110.63 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Genentech USA, INC. | $97.64 | 2022-2023 | Venclexta, Tecentriq |
| Genzyme Corporation | $90.67 | 2021-2025 | |
| Lilly USA, LLC | $88.47 | 2022-2025 | Jaypirca, Verzenio |
| Coherus Oncology, INC. | $86.95 | 2020-2024 | |
| Puma Biotechnology, INC. | $86.25 | 2020-2025 | |
| Eisai INC. | $81.91 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $78.27 | 2025 | Libtayo, Lynozyfic |
| Stemline Therapeutics INC. | $70.84 | 2025 | Orserdu |
| Abbvie INC. | $70.68 | 2023-2025 | |
| Genmab U.S., INC. | $68.40 | 2024-2025 | Epkinly |
| Boston Scientific Corporation | $67.28 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Takeda Pharmaceuticals U.S.A., INC. | $66.37 | 2022-2024 | Alunbrig |
| Amgen INC. | $63.65 | 2021-2023 | Xgeva, Vectibix, Nplate |
| Merck Sharp & Dohme LLC | $63.60 | 2023-2025 | Welireg, Keytruda |
| Tactile Systems Technology INC | $56.24 | 2022-2024 | Flexitouch Plus, Entre Plus |
| Karyopharm Therapeutics INC. | $56.20 | 2024-2025 | Xpovio |
| Rigel Pharmaceuticals, INC. | $53.10 | 2022-2023 | Tavalisse, Rezlidhia |
| Shield Therapeutics INC | $48.31 | 2023-2025 | Accrufer |
| Pharmacosmos Therapeutics INC. | $48.18 | 2025 | Monoferric |
| Tersera Therapeutics LLC | $46.59 | 2023-2025 | Xermelo |
| Legend Biotech USA INC. | $46.43 | 2024-2025 | Carvykti |
| Mirati Therapeutics, INC. | $40.82 | 2023 | Krazati |
| Emd Serono, INC. | $39.12 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $33.31 | 2022-2024 | |
| Blueprint Medicines Corporation | $32.50 | 2020-2024 | Ayvakit |
| Array Biopharma INC | $31.26 | 2025 | Braftovi, Lorbrena |
| Neurocrine Biosciences, INC. | $30.00 | 2025 | |
| Acceleron Pharma, INC. | $29.85 | 2020-2021 | |
| G1 Therapeutics, INC. | $27.47 | 2023 | Cosela |
| Sumitomo Pharma America, INC. | $25.13 | 2023 | Orgovyx |
| Secura Bio, INC. | $19.81 | 2022 | |
| Kyowa Kirin, INC. | $19.35 | 2024 | Poteligeo |
| Recordati_rare_diseases_inc. | $17.12 | 2025 | Enjaymo |
| Kite Pharma, INC. | $16.56 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.46 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.20 | 2021 | |
| Taiho Oncology, INC. | $13.83 | 2025 | |
| Servier Pharmaceuticals LLC | $13.53 | 2024 | |
| Sirtex Medical INC | $11.67 | 2025 | Sir-Spheres Microspheres |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usman Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.